Welcome to Paid Research Studies




  • Condition:   Neurofibromatosis 1
    Intervention:   Other: Transcranial direct current stimulation
    Sponsor:   University of Manchester
    Recruiting

  • Condition:   Neurofibromatosis Type 1
    Interventions:   Other: Neuropsychological evaluation;   Other: Evaluation of the reading assistance technique
    Sponsor:   University Hospital, Toulouse
    Not yet recruiting

  • Condition:   Neurofibromatosis Type 1
    Interventions:   Device: Magnetic resonance imaging;   Drug: Gadolinium contrast
    Sponsors:   Washington University School of Medicine;   St. Louis Children's Hospital
    Recruiting

  • Condition:   NEUROFIBROMATOSIS 1
    Intervention:   Procedure: PDT Treatment
    Sponsor:   Harry T Whelan, MD
    Recruiting

  • Conditions:   Neurofibromatosis 1;   Neurofibroma, Plexiform
    Intervention:   Behavioral: Medication Event Monitoring System (MEMS)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Neurofibromatosis 1 and 2 (NF1 and NF2)
    Intervention:   Behavioral: hand-held dynamometer
    Sponsor:   New York University School of Medicine
    Recruiting

  • Condition:   Neurofibromatosis Type 1
    Interventions:   Drug: Lamotrigine;   Drug: Placebo
    Sponsors:   Erasmus Medical Center;   Universitaire Ziekenhuizen Leuven;   ZonMw: The Netherlands Organisation for Health Research and Development;   Hospital Sant Joan de Deu
    Recruiting

  • Condition:   Neurofibromatosis Type 1 (NF1)
    Intervention:   Drug: Cholecalciferol
    Sponsors:   University of Utah;   U.S. Army Medical Research and Materiel Command;   Universitätsklinikum Hamburg-Eppendorf;   University of British Columbia;   Children's Hospital Medical Center, Cincinnati
    Recruiting

  • Condition:   Neurofibromatoses
    Interventions:   Behavioral: Stress and Symptom Management Program 1;   Behavioral: Stress and Symptom Management Program 2
    Sponsors:   Massachusetts General Hospital;   United States Department of Defense
    Not yet recruiting

  • Conditions:   Neurofibromatosis 1;   Plexiform Neurofibromas
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neurofibromatosis Type 1;   Muscle Weakness
    Interventions:   Device: Whole-body vibration;   Other: Muscle strengthening exercises
    Sponsors:   Manchester University NHS Foundation Trust;   Manchester Metropolitan University
    Not yet recruiting

  • Conditions:   Neurofibromatosis 1;   Neurofibromatosis 2;   Schwannomatosis
    Intervention:  
    Sponsor:   The Children's Tumor Foundation
    Recruiting

  • Conditions:   Neurofibromatosis Type 1;   Plexiform Neurofibromas
    Intervention:   Behavioral: Acceptance and Commitment Therapy (ACT)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neurofibromatosis Type 1;   Plexiform Neurofibroma
    Intervention:   Drug: Binimetinib
    Sponsors:   University of Alabama at Birmingham;   Array BioPharma;   Pacific Pediatric Neuro-Oncology Consortium
    Recruiting

  • Condition:   Neurofibroma, Plexiform
    Intervention:   Drug: Imatinib Mesylate
    Sponsors:   Indiana University;   Food and Drug Administration (FDA)
    Recruiting

  • Condition:   NF type1 With Inoperable Plexiform Neurofibromas
    Intervention:   Drug: Selumetinib
    Sponsor:   AstraZeneca
    Available

  • Conditions:   Neurofibromatosis;   MPNST
    Interventions:   Procedure: MRI, FDG-PET/CT scans;   Drug: [18F]-FLT-PET/CT scans
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   NF1;   Neurofibromatosis;   Plexiform Neurofibromas
    Intervention:   Drug: Cabozantinib
    Sponsor:   University of Alabama at Birmingham
    Recruiting

  • Conditions:   Neurofibromatosis Type 1;   Tumors of the Central Nervous System
    Intervention:   Diagnostic Test: Collection of Stem Cells
    Sponsor:   Children's Research Institute
    Recruiting

  • Conditions:   Autism Spectrum Disorder;   Neurofibromatosis 1
    Interventions:   Drug: Lovastatin 60 MG;   Drug: Placebos
    Sponsor:   University of Coimbra
    Recruiting

  • Conditions:   NF1;   Congenital Pseudarthrosis of Tibia
    Interventions:   Device: INFUSE Bone Graft (BMP-2);   Procedure: Control Group
    Sponsors:   University of Alabama at Birmingham;   The Children's Tumor Foundation;   Medtronic
    Recruiting

  • Conditions:   Parents of Children With Cancer;   Parents of Children With NF1;   Parents of Children With Neurofibromatosis Type I
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neurofibromatosis 1;   Child;   Neurofibroma, Plexiform
    Intervention:   Drug: Trametinib
    Sponsors:   Region Skane;   Novartis
    Recruiting

  • Conditions:   Neurofibromatosis Type 1;   Plexiform Neurofibroma;   Optic Nerve Glioma
    Intervention:   Drug: Selumetinib
    Sponsors:   Great Ormond Street Hospital for Children NHS Foundation Trust;   AstraZeneca
    Not yet recruiting

  • Conditions:   Low Grade Glioma;   Neurofibromatosis Type 1;   Visual Pathway Glioma
    Interventions:   Drug: Carboplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Selumetinib;   Drug: Selumetinib Sulfate;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Neurofibromatosis 2;   Dermatology/Skin - Other
    Intervention:   Other: no intervention
    Sponsor:   Centre Hospitalier Universitaire de Nice
    Recruiting

  • Conditions:   Neurofibromatosis Type 1;   Learning Disability;   Reading Disability;   NF1
    Interventions:   Drug: Lovastatin;   Behavioral: reading tutoring intervention;   Drug: Placebo Oral Tablet;   Behavioral: Other Academic "sham" tutoring
    Sponsors:   Vanderbilt University;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Neurofibromatosis Type 1;   Malignant Peripheral Nerve Sheath Tumor;   Plexiform Neurofibroma;   Optic Glioma;   Neurofibroma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neurofibromatosis 2;   Vestibular Schwannoma;   Meningioma;   Ependymoma;   Glioma
    Intervention:   Drug: Selumetinib
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   AstraZeneca
    Recruiting

  • Conditions:   Cafe Au Lait Spot;   Cutaneous Neurofibroma;   Dysplasia;   Lisch Nodule;   Neurofibromatosis Type 1;   NF1 Gene Mutation;   Optic Nerve Glioma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Selumetinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neurofibroma, Plexiform;   Precursor Cell Lymphoblastic Leukemia-Lymphoma;   Leukemia, Prolymphocytic, Acute;   Sarcoma
    Intervention:   Drug: PLX3397
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non-small Cell Lung Cancer
    Intervention:   Drug: Trametinib
    Sponsors:   Collin Blakely;   Novartis Pharmaceuticals;   American Cancer Society, Inc.
    Recruiting

  • Conditions:   Spinal Cord Disease;   Intracranial Central Nervous System Disorder;   Neurologic Disorders;   Brain Neoplasms
    Intervention:  
    Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting

  • Conditions:   Low-grade Glioma;   Plexiform Neurofibroma;   Central Nervous System Glioma
    Intervention:   Drug: Trametinib
    Sponsors:   St. Justine's Hospital;   Montreal Children's Hospital of the MUHC;   CHU de Quebec-Universite Laval
    Recruiting

  • Conditions:   Malignant Peripheral Nerve Sheath Tumors;   Neurofibromatosis 1
    Interventions:   Drug: Selumetinib;   Drug: Sirolimus
    Sponsors:   Sarcoma Alliance for Research through Collaboration;   United States Department of Defense;   AstraZeneca
    Not yet recruiting

  • Conditions:   Metastatic Malignant Peripheral Nerve Sheath Tumor;   Neurofibromatosis Type 1;   Recurrent Malignant Peripheral Nerve Sheath Tumor
    Interventions:   Procedure: Computed Tomography;   Other: Laboratory Biomarker Analysis;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter;   Other: Quality-of-Life Assessment;   Procedure: Single Photon Emission Computed Tomography
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Vestibular Schwannoma;   Acoustic Neuroma;   Neurofibromatosis 2
    Interventions:   Drug: Aspirin;   Drug: Placebo
    Sponsors:   Massachusetts Eye and Ear Infirmary;   United States Department of Defense;   Massachusetts General Hospital
    Recruiting

  • Conditions:   Sickle Cell Disease;   Solid Tumor;   Leukemia;   Neurofibromatosis
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   KEAP1 Gene Mutation;   Metastatic Malignant Solid Neoplasm;   NF1 Gene Mutation;   NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor;   NFE2L2 Gene Mutation;   STK11 Gene Mutation;   Unresectable Malignant Solid Neoplasm
    Interventions:   Drug: Glutaminase Inhibitor CB-839 Hydrochloride;   Other: Pharmacodynamic Study
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Tuberous Sclerosis Complex
    Intervention:  
    Sponsors:   Translational Genomics Research Institute;   United States Department of Defense
    Recruiting

  • Conditions:   Neoplasms;   Adenomatous Polyposis Coli;   Neurofibroma, Plexiform;   Myelodysplastic Syndromes
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Low Grade Glioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Neurofibromatosis Type 1;   Recurrent Visual Pathway Glioma;   Refractory Neurofibromatosis Type 1;   Refractory Visual Pathway Glioma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Selumetinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Activating RAS Mutation;   Blasts Under 20 Percent of Bone Marrow Nucleated Cells;   Blasts Under 20 Percent of Peripheral Blood White Cells;   Juvenile Myelomonocytic Leukemia;   Monosomy 7;   Neurofibromatosis Type 1;   NF1 Gene Mutation;   PTPN11 Gene Mutation;   Splenomegaly
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Headache;   Tumor;   Seizure Disorder;   Neurofibromatoses;   Hydrocephalus;   Abdominal Neoplasm;   Spine Deformity
    Interventions:   Drug: propofol;   Drug: Dexmedetomidine
    Sponsor:   Medical College of Wisconsin
    Recruiting

  • Conditions:   Advanced Malignant Neoplasm;   Castleman Disease;   Digestive System Carcinoma;   Erdheim-Chester Disease;   Lip and Oral Cavity Carcinoma;   Lymphangioleiomyomatosis;   Malignant Endocrine Neoplasm;   Malignant Female Reproductive System Neoplasm;   Malignant Male Reproductive System Neoplasm;   Malignant Neoplasm;   Malignant Respiratory Tract Neoplasm;   Malignant Thoracic Neoplasm;   Malignant Urinary System Neoplasm;   Mesothelial Neoplasm;   Metastatic Malignant Neoplasm;   Metastatic Urothelial Carcinoma;   Neurofibromatosis Type 2;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Breast Carcinoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Digestive System Carcinoma;   Recurrent Female Reproductive System Carcinoma;   Recurrent Male Reproductive System Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Pharyngeal Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Malignant Neoplasm;   Soft Tissue Neoplasm;   Stage III Breast Cancer AJCC v7;   Stage III Pharyngeal Cancer;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Stage IV Pharyngeal Cancer;   Stage IVA Pharyngeal Cancer;   Stage IVB Pharyngeal Cancer;   Stage IVC Pharyngeal Cancer;   Thyroid Gland Neoplasm
    Interventions:   Biological: Bevacizumab;   Biological: Cetuximab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Temsirolimus;   Drug: Valproic Acid
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Impaired Synaptic Plasticity;   Impaired Cognition
    Interventions:   Drug: Lovastatin;   Drug: Lamotrigine
    Sponsor:   Technische Universität München
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   ARAF Gene Mutation;   BRAF Gene Mutation;   GNA11 Gene Mutation;   GNAQ Gene Mutation;   HRAS Gene Mutation;   KRAS Gene Mutation;   MAP2K1 Gene Mutation;   MAPK1 Gene Mutation;   NF1 Gene Mutation;   NRAS Gene Mutation;   Recurrent Ependymal Tumor;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Histiocytic and Dendritic Cell Neoplasm;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Histiocytic and Dendritic Cell Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Pharmacokinetic Study;   Drug: Ulixertinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   BRAF Gene Mutation;   GNA11 Gene Mutation;   GNAQ Gene Mutation;   Histiocytosis;   HRAS Gene Mutation;   KRAS Gene Mutation;   NF1 Gene Mutation;   NRAS Gene Mutation;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Selumetinib;   Drug: Selumetinib Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Liposarcoma;   Malignant Peripheral Nerve Sheath Tumors;   Alveolar Soft Part Sarcoma;   Ewing Sarcoma;   Sarcoma
    Interventions:   Drug: Selinexor;   Drug: Ixazomib
    Sponsors:   Matthew Ingham;   Karyopharm Therapeutics Inc;   Takeda
    Not yet recruiting

  • Conditions:   Sarcoma;   Fibrosarcoma;   Leiomyosarcoma;   Liposarcoma;   Myosarcoma;   Histiocytic Sarcoma;   Synovial Sarcoma;   Lymphangiosarcoma;   Malignant Peripheral Nerve Sheath Tumors;   Myxofibrosarcoma;   Myxoid Liposarcoma;   Undifferentiated Sarcoma;   Pleomorphic Liposarcoma;   Undifferentiated Pleomorphic Sarcoma;   Dedifferentiated Liposarcoma;   Pleomorphic Rhabdomyosarcoma;   Malignant Triton Tumor
    Interventions:   Drug: Sequential chemotherapy - 3 courses of AI;   Radiation: Hypofractionated radiotherapy
    Sponsor:   Maria Sklodowska-Curie Institute - Oncology Center
    Recruiting

  • Conditions:   Pediatric Solid Tumor;   Germ Cell Tumor;   Retinoblastoma;   Hepatoblastoma;   Wilms Tumor;   Rhabdoid Tumor;   Carcinoma;   Osteosarcoma;   Ewing Sarcoma;   Rhabdomyosarcoma;   Synovial Sarcoma;   Clear Cell Sarcoma;   Malignant Peripheral Nerve Sheath Tumors;   Desmoplastic Small Round Cell Tumor;   Soft Tissue Sarcoma;   Neuroblastoma
    Interventions:   Biological: second generation 4-1BBζ EGFR806-EGFRt;   Biological: second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
    Sponsor:   Seattle Children's Hospital
    Recruiting

  • Conditions:   Carcinoma, Non-Small-Cell Lung;   Thyroid Neoplasms;   Sarcoma;   Colorectal Neoplasms;   Salivary Gland Neoplasms;   Biliary Tract Neoplasms;   Brain Neoplasm, Primary;   Melanoma;   Glioblastoma;   Bile Duct Neoplasms;   Astrocytoma;   Head and Neck Squamous Cell Carcinoma;   Pontine Glioma;   Pancreatic Neoplasms;   Ovarian Neoplasms;   Carcinoma, Renal Cell;   Cholangiocarcinoma;   Skin Carcinoma;   Carcinoma, Bronchogenic;   Bronchial Neoplasms;   Lung Neoplasms;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Neoplasms, Nerve Tissue;   Nevi and Melanomas;   Intestinal Neoplasms;   Thyroid Cancer;   GIST;   Malignant Peripheral Nerve Sheath Tumors;   Breast Secretory Carcinoma;   Uterine Neoplasms;   Fibrosarcoma;   Infantile Fibrosarcoma;   Congenital Mesoblastic Nephroma;   Central Nervous System Neoplasms
    Intervention:   Drug: LOXO-195
    Sponsors:   Loxo Oncology, Inc.;   Bayer
    Recruiting

  • Condition:   Malignant Peripheral Nerve Sheath Tumors
    Intervention:  
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Metastatic Angiosarcoma;   Metastatic Epithelioid Sarcoma;   Metastatic Fibrosarcoma;   Metastatic Leiomyosarcoma;   Metastatic Liposarcoma;   Metastatic Malignant Peripheral Nerve Sheath Tumor;   Metastatic Synovial Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Myxofibrosarcoma;   Pleomorphic Rhabdomyosarcoma;   Stage III Soft Tissue Sarcoma;   Stage IV Soft Tissue Sarcoma;   Undifferentiated (Embryonal) Sarcoma
    Interventions:   Drug: Doxorubicin;   Drug: Ribociclib
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Sarcoma;   Malignant Peripheral Nerve Sheath Tumors
    Interventions:   Drug: PLX3397;   Drug: Sirolimus
    Sponsors:   Gulam Manji;   Plexxikon
    Recruiting

  • Conditions:   Sarcoma, Soft Tissue;   Soft Tissue Sarcoma;   Undifferentiated Pleomorphic Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Synovial Sarcoma;   Myxofibrosarcoma;   Angiosarcoma;   Fibrosarcoma;   Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma
    Interventions:   Drug: Dexrazoxane;   Drug: Doxorubicin;   Drug: Olaratumab
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Solid Tumors
    Intervention:   Drug: RMC-4630
    Sponsors:   Revolution Medicines, Inc.;   Sanofi
    Recruiting